A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

by , | Dec 20, 2022 | C19 (COVID-19), VC19 (VACCINES COVID-19), VE (VACCINE EFFECTIVENESS), VS (VACCINE SAFETY)

Motivation

PROTOCOL for Pfizer Phase 1/2 & 3 SARS-CoV-2 RNA Vaccine Trials. This specifies the trial design and rules. PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines)

Author

Pfizer. BioNTech.

Submitted By

Dr Herman Edeling

Supported By

Dr Stephen Schmidt

Type of Article

Trial protocol